Profile data is unavailable for this security.
About the company
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
- Revenue in USD (TTM)10.06bn
- Net income in USD2.86bn
- Incorporated1995
- Employees17.02k
- LocationIntuitive Surgical Inc1020 Kifer RoadSUNNYVALE 94086United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.intuitive.com/en-us/about-us/company
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boston Scientific Corp | 20.08bn | 2.90bn | 114.04bn | 59.00k | 39.63 | 4.70 | 26.76 | 5.68 | 1.94 | 1.94 | 13.43 | 16.34 | 0.4833 | 2.16 | 7.32 | 340,254.30 | 6.97 | 4.57 | 8.18 | 5.31 | 69.01 | 69.07 | 14.41 | 10.67 | 1.08 | 12.50 | 0.3185 | 0.00 | 19.87 | 15.16 | 56.40 | -- | 10.91 | -- |
| Medtronic PLC | 35.48bn | 4.61bn | 125.38bn | 95.00k | 27.27 | 2.56 | 16.24 | 3.53 | 3.58 | 3.58 | 27.55 | 38.17 | 0.3911 | 2.07 | 5.69 | 373,505.30 | 5.12 | 4.55 | 5.81 | 5.15 | 65.16 | 66.25 | 13.08 | 13.07 | 1.87 | 8.53 | 0.3633 | 84.20 | 3.62 | 3.01 | 26.82 | -0.2723 | 8.91 | 5.33 |
| Stryker Corp | 25.12bn | 3.25bn | 148.28bn | 56.00k | 46.14 | 6.61 | 33.40 | 5.90 | 8.40 | 8.40 | 64.98 | 58.61 | 0.5531 | 1.76 | 6.26 | 448,500.00 | 7.15 | 7.04 | 8.61 | 8.46 | 64.57 | 64.06 | 12.92 | 13.26 | 1.21 | 11.73 | 0.4143 | 41.77 | 11.16 | 11.84 | 8.45 | 15.21 | 9.34 | 3.02 |
| Danaher Corp | 24.57bn | 3.60bn | 148.95bn | 58.00k | 41.86 | 2.83 | 24.63 | 6.06 | 5.03 | 5.05 | 34.31 | 74.32 | 0.3052 | 4.16 | 6.60 | 423,586.20 | 4.47 | 5.74 | 4.89 | 6.34 | 59.23 | 59.98 | 14.65 | 18.98 | 1.51 | 10.87 | 0.2596 | 16.35 | 2.90 | 1.97 | -7.67 | 0.5076 | 7.88 | 12.51 |
| Intuitive Surgical Inc | 10.06bn | 2.86bn | 178.81bn | 17.02k | 63.92 | 10.03 | 50.32 | 17.77 | 7.88 | 7.88 | 27.75 | 50.19 | 0.5135 | 2.06 | 7.31 | 591,310.80 | 14.68 | 13.20 | 16.33 | 14.71 | 66.00 | 67.14 | 28.58 | 26.96 | 3.96 | -- | 0.00 | 0.00 | 20.51 | 18.22 | 22.97 | 21.91 | 9.59 | -- |
| Thermo Fisher Scientific Inc | 44.56bn | 6.70bn | 193.58bn | 125.00k | 29.38 | 3.67 | 20.29 | 4.34 | 17.74 | 17.74 | 117.87 | 142.17 | 0.4291 | 5.05 | 4.81 | -- | 6.51 | 7.12 | 7.56 | 8.36 | 41.07 | 42.87 | 15.18 | 15.87 | 1.53 | 19.30 | 0.4239 | 8.14 | 3.91 | 6.70 | 5.82 | 1.01 | 0.6826 | 15.14 |
| Abbott Laboratories | 44.33bn | 6.52bn | 202.18bn | 115.00k | 31.17 | 3.88 | 20.97 | 4.56 | 3.73 | 3.73 | 25.36 | 30.02 | 0.5273 | 3.03 | 5.97 | 385,460.90 | 7.76 | 10.33 | 9.55 | 12.72 | 56.66 | 56.20 | 14.72 | 18.61 | 1.18 | 61.89 | 0.1968 | 46.20 | 5.67 | 5.08 | -51.32 | 7.73 | -0.0552 | 10.76 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 30.06m | 8.48% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 18.86m | 5.32% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 15.70m | 4.43% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 12.03m | 3.39% |
| Geode Capital Management LLCas of 31 Dec 2025 | 8.23m | 2.32% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 7.86m | 2.22% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 5.58m | 1.58% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 5.04m | 1.42% |
| BlackRock Advisors (UK) Ltd.as of 31 Dec 2025 | 3.81m | 1.08% |
| Fisher Asset Management LLCas of 31 Dec 2025 | 3.78m | 1.07% |
